The "Paranasal Sinus Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 5-10 companies and 5-10 pipeline drugs in Paranasal sinus cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Symptoms can include blocked sinuses, pain in sinus areas, nosebleeds, lump inside the nose that does not heal, and swelling or other trouble with the eyes, such as double vision or the eyes pointing in different directions.
Diagnosing Paranasal sinus cancer requires physical assessments of nose, face, and neck. Furthermore, clinicians also recommend screening procedures such as X-rays, MRI, CT scan, nasoscopy, laryngoscopy to view inside the nose for abnormal areas. Sometimes biopsy is also done to detect the presence of malignant cells inside the sinus cavity.
Different types of treatments are available for patients with paranasal sinus cancer. The currently used treatments include surgery, radiation therapy, and chemotherapy which comprises of administration of several approved drugs such as cisplatin, docetaxel, methotrexate, and others.
Paranasal sinus cancer Emerging Drugs Chapters
This segment of the Paranasal sinus cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Paranasal sinus cancer Emerging Drugs
Exelixis' lead drug candidate, Cabozantinib, is an orally administered small molecule receptor tyrosine kinase inhibitor that inhibits specific tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2 and suppress metastases, and oncogeneses. Preclinical data demonstrated that Cabozantinib is used for the treatment of head and neck as well as paranasal sinus squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery.
Celgene drug motolimod is currently being evaluated for the treatment of Paranasal sinus cancer. Motolimod, a toll-like receptor 8 (TLR8) agonist, stimulates myeloid dendritic cells, monocytes, and natural killer cells in the blood and tumor microenvironment, inducing a proinflammatory immune response. In the phase I trial, Tumor immune modulation will be evaluated by counting the number of tumor infiltration CD8+ T cells before and after treatment.
Paranasal sinus cancer: Therapeutic Assessment
This segment of the report provides insights about the different Paranasal sinus cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Paranasal sinus cancer
There are approx. 10+ key companies which are developing the therapies for Paranasal sinus cancer. The companies which have their Paranasal sinus cancer drug candidates in the mid to advanced stage, i. e. phase III and Phase II include, Exelixis and others.
This report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Paranasal sinus cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Paranasal sinus cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Paranasal sinus cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Paranasal sinus cancer drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Paranasal sinus cancer R&D. The therapies under development are focused on novel approaches to treat/improve Paranasal sinus cancer.
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Paranasal sinus cancer drugs?
How many Paranasal sinus cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Paranasal sinus cancer?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Paranasal sinus cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Paranasal sinus cancer and their status?
What are the key designations that have been granted to the emerging drugs?
S. L.A. Pharma AG
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yle3kc
View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005341/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900